Could a common painkiller boost immunotherapy in liver cancer?

NCT ID NCT07174570

First seen Sep 30, 2025 · Last updated May 13, 2026 · Updated 23 times

Summary

This study tests whether adding celecoxib (a pain reliever) to standard immunotherapy drugs (durvalumab and tremelimumab) can help control advanced liver cancer that has spread. About 39 adults with advanced or metastatic hepatocellular carcinoma will receive the combination. The goal is to see if the combo improves progression-free survival and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory Saint Joseph's Hospital

    RECRUITING

    Atlanta, Georgia, 30342, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Emory University Hospital Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Grady Health System

    NOT_YET_RECRUITING

    Atlanta, Georgia, 30303, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.